 | • レポートコード：MRC2304D086 • 出版社/出版日：Transparency Market Research / 2023年1月12日 • レポート形態：英文、PDF、190ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の当調査レポートでは、遺伝子ベクターの世界市場を分析し、市場実態を明らかにしています。本書は、序論、仮定＆調査手法、エグゼクティブサマリー、市場概要、キーインサイト、市場分析＆予測、ベクター種類別（レンチウイルス、アデノウイルス、アデノ随伴ウイルス、プラスミドDNA、その他）分析、用途別（遺伝子治療、ワクチン、その他）分析、疾患別（遺伝性疾患、がん、感染症、その他）分析、エンドユーザー別（科学研究、CRO、CDMO）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などを収録しています。また、Lonza、Merck KGaA、Oxford Biomedica、CGT Catapult、Charles River Laboratories、uniQure N.V.、FUJIFILM Diosynth Biotechnologies、Spark Therapeutics, Inc.などの企業情報を掲載しています。 ・序論 ・仮定＆調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・市場分析＆予測 ・世界の遺伝子ベクター市場規模：ベクター種類別 - レンチウイルスの市場規模 - アデノウイルスの市場規模 - アデノ随伴ウイルスの市場規模 - プラスミドDNAの市場規模 - その他ベクター種類の市場規模 ・世界の遺伝子ベクター市場規模：用途別 - 遺伝子治療における市場規模 - ワクチンにおける市場規模 - その他用途における市場規模 ・世界の遺伝子ベクター市場規模：疾患別 - 遺伝性疾患における市場規模 - がんにおける市場規模 - 感染症における市場規模 - その他疾患における市場規模 ・世界の遺伝子ベクター市場規模：エンドユーザー別 - CRO科学研究における市場規模 - CDMOにおける市場規模 ・世界の遺伝子ベクター市場規模：地域別 - 北米の遺伝子ベクター市場規模 - ヨーロッパの遺伝子ベクター市場規模 - アジア太平洋の遺伝子ベクター市場規模 - 中南米のアルミニウムスラグ市場規模 - 中東・アフリカのアルミニウムスラグ市場規模 ・競争状況 |
Gene Vector Market – Scope of Report
TMR’s report on the global gene vector market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global gene vector market for the period 2017–2031, considering 2022 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global gene vector market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the gene vector market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global gene vector market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global gene vector market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global gene vector market.
The report delves into the competitive landscape of the global gene vector market. Key players operating in the global gene vector market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global gene vector market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market gene vector.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
• Industry Sources:
o WorldWideScience.org
o Elsevier, Inc.
o National Institutes of Health (NIH)
o PubMed
o NCBI
o Department of Health Care Service
• Trade Data Sources
o Trade Map
o UN Comtrade
o Trade Atlas
• Company Information
o OneSource Business Browser
o Hoover’s
o Factiva
o Bloomberg
• Mergers & Acquisitions
o Thomson Mergers & Acquisitions
o MergerStat
o Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Gene Vector Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Gene Vector Market Analysis and Forecasts, 2017 – 2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Technological Advancements
5.2. Major Research Institutes Involved
5.3. Disease Prevalence & Incidence Rate globally with key countries
5.4. COVID-19 Pandemic Impact on Industry
6. Global Gene Vector Market Analysis and Forecast, by Vector Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Vector Type, 2017 – 2031
6.3.1. Lentivirus
6.3.2. Adenovirus
6.3.3. Adeno-associated Virus (AAV)
6.3.4. Plasmid DNA
6.3.5. Others
6.4. Market Attractiveness, by Vector Type
7. Global Gene Vector Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2017 – 2031
7.3.1. Gene Therapy
7.3.2. Vaccinology
7.3.3. Others
7.4. Market Attractiveness, by Application
8. Global Gene Vector Market Analysis and Forecast, by Disease
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Disease, 2017 – 2031
8.3.1. Genetic Disorder
8.3.2. Cancer
8.3.3. Infectious Disease
8.3.4. Others
8.4. Market Attractiveness, by Disease
9. Global Gene Vector Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by End-user, 2017 – 2031
9.3.1. Scientific Research
9.3.2. CRO
9.3.3. CDMO
9.3.4. Others (Pharmaceutical, Biotechnology Companies)
9.4. Market Attractiveness, by End-user
10. Global Gene Vector Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Country/Region
11. North America Gene Vector Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Vector Type, 2017 – 2031
11.2.1. Lentivirus
11.2.2. Adenovirus
11.2.3. Adeno-associated Virus (AAV)
11.2.4. Plasmid DNA
11.2.5. Others
11.3. Market Value Forecast, by Application, 2017 – 2031
11.3.1. Gene Therapy
11.3.2. Vaccinology
11.3.3. Others
11.4. Market Value Forecast, by Disease, 2017 – 2031
11.4.1. Genetic Disorder
11.4.2. Cancer
11.4.3. Infectious Disease
11.4.4. Others
11.5. Market Value Forecast, by End-user, 2017 – 2031
11.5.1. Scientific Research
11.5.2. CRO
11.5.3. CDMO
11.5.4. Others (Pharmaceutical, Biotechnology Companies)
11.6. Market Value Forecast, by Country, 2017 – 2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Vector Type
11.7.2. By Application
11.7.3. By Disease
11.7.4. By End-user
11.7.5. By Country
12. Europe Gene Vector Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Vector Type, 2017 – 2031
12.2.1. Lentivirus
12.2.2. Adenovirus
12.2.3. Adeno-associated Virus (AAV)
12.2.4. Plasmid DNA
12.2.5. Others
12.3. Market Value Forecast, by Application, 2017 – 2031
12.3.1. Gene Therapy
12.3.2. Vaccinology
12.3.3. Others
12.4. Market Value Forecast, by Disease, 2017 – 2031
12.4.1. Genetic Disorder
12.4.2. Cancer
12.4.3. Infectious Disease
12.4.4. Others
12.5. Market Value Forecast, by End-user, 2017 – 2031
12.5.1. Scientific Research
12.5.2. CRO
12.5.3. CDMO
12.5.4. Others (Pharmaceutical, Biotechnology Companies)
12.6. Market Value Forecast, by Country, 2017 – 2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Vector Type
12.7.2. By Application
12.7.3. By Disease
12.7.4. By End-user
12.7.5. By Country
13. Asia Pacific Gene Vector Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Vector Type, 2017 – 2031
13.2.1. Lentivirus
13.2.2. Adenovirus
13.2.3. Adeno-associated Virus (AAV)
13.2.4. Plasmid DNA
13.2.5. Others
13.3. Market Value Forecast, by Application, 2017 – 2031
13.3.1. Gene Therapy
13.3.2. Vaccinology
13.3.3. Others
13.4. Market Value Forecast, by Disease, 2017 – 2031
13.4.1. Genetic Disorder
13.4.2. Cancer
13.4.3. Infectious Disease
13.4.4. Others
13.5. Market Value Forecast, by End-user, 2017 – 2031
13.5.1. Scientific Research
13.5.2. CRO
13.5.3. CDMO
13.5.4. Others (Pharmaceutical, Biotechnology Companies)
13.6. Market Value Forecast, by Country, 2017 – 2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Vector Type
13.7.2. By Application
13.7.3. By Disease
13.7.4. By End-user
13.7.5. By Country
14. Latin America Gene Vector Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Vector Type, 2017 – 2031
14.2.1. Lentivirus
14.2.2. Adenovirus
14.2.3. Adeno-associated Virus (AAV)
14.2.4. Plasmid DNA
14.2.5. Others
14.3. Market Value Forecast, by Application, 2017 – 2031
14.3.1. Gene Therapy
14.3.2. Vaccinology
14.3.3. Others
14.4. Market Value Forecast, by Disease, 2017 – 2031
14.4.1. Genetic Disorder
14.4.2. Cancer
14.4.3. Infectious Disease
14.4.4. Others
14.5. Market Value Forecast, by End-user, 2017 – 2031
14.5.1. Scientific Research
14.5.2. CRO
14.5.3. CDMO
14.5.4. Others (Pharmaceutical, Biotechnology Companies)
14.6. Market Value Forecast, by Country, 2017 – 2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Vector Type
14.7.2. By Application
14.7.3. By Disease
14.7.4. By End-user
14.7.5. By Country
15. Middle East & Africa Gene Vector Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Vector Type, 2017 – 2031
15.2.1. Lentivirus
15.2.2. Adenovirus
15.2.3. Adeno-associated Virus (AAV)
15.2.4. Plasmid DNA
15.2.5. Others
15.3. Market Value Forecast, by Application, 2017 – 2031
15.3.1. Gene Therapy
15.3.2. Vaccinology
15.3.3. Others
15.4. Market Value Forecast, by Disease, 2017 – 2031
15.4.1. Genetic Disorder
15.4.2. Cancer
15.4.3. Infectious Disease
15.4.4. Others
15.5. Market Value Forecast, by End-user, 2017 – 2031
15.5.1. Scientific Research
15.5.2. CRO
15.5.3. CDMO
15.5.4. Others (Pharmaceutical, Biotechnology Companies)
15.6. Market Value Forecast, by Country, 2017 – 2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Vector Type
15.7.2. By Application
15.7.3. By Disease
15.7.4. By End-user
15.7.5. By Country
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of companies)
16.2. Market Share Analysis By Company (2021)
16.3. Company Profiles
16.3.1. Lonza
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Merck KGaA
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Oxford Biomedica
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. CGT Catapult
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Charles River Laboratories
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. uniQure N.V.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. FUJIFILM Diosynth Biotechnologies
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Spark Therapeutics, Inc.
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Other Prominent Players
